Richter, N., I. Allendorf, O. A. Onur, L. W. Kracht, M. Dietlein, M. Tittgemeyer, B. Neumaier, G. R. Fink and J. Kukolja: The integrity of the cholinergic system determines memory performance in healthy elderly. In: NeuroImage 100, Oct., 481-488 (2014).
doi: 10.1016/j.neuroimage.2014.06.031
Richter, N., I. Allendorf, O. A. Onur, L. W. Kracht, M. Dietlein, M. Tittgemeyer, B. Neumaier, G. R. Fink and J. Kukolja: The integrity of the cholinergic system determines memory performance in healthy elderly. In: NeuroImage 100, Oct., 481-488 (2014).
doi: 10.1016/j.neuroimage.2014.06.031
Richter, N., I. Allendorf, O. A. Onur, L. W. Kracht, M. Dietlein, M. Tittgemeyer, B. Neumaier, G. R. Fink and J. Kukolja: The integrity of the cholinergic system determines memory performance in healthy elderly. In: NeuroImage 100, Oct., 481-488 (2014).
doi: 10.1016/j.neuroimage.2014.06.031
Kobe, C., M. Scheffler, A. Holstein, T. Zander, L. Nogova, A. A. Lammertsma, R. Boellaard, B. Neumaier, R. T. Ullrich, M. Dietlein, J. Wolf and D. Kahraman: Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. In: European Journal of Nuclear Medicine and Molecular Imaging 39, 7, 1117-1127 (2012).
doi: 10.1007/s00259-012-2118-8
Kobe, C., M. Scheffler, A. Holstein, T. Zander, L. Nogova, A. A. Lammertsma, R. Boellaard, B. Neumaier, R. T. Ullrich, M. Dietlein, J. Wolf and D. Kahraman: Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. In: European Journal of Nuclear Medicine and Molecular Imaging 39, 7, 1117-1127 (2012).
doi: 10.1007/s00259-012-2118-8
Scheffler, M., C. Kobe, T. Zander, L. Nogova, D. Kahraman, R. K. Thomas, B. Neumaier, M. Dietlein and J. Wolf: Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [ 18F]fluorothymidine (FLT-)PET. In: Lung Cancer 77, 3, 617-620 (2012).
doi: 10.1016/j.lungcan.2012.05.110
Scheffler, M., C. Kobe, T. Zander, L. Nogova, D. Kahraman, R. K. Thomas, B. Neumaier, M. Dietlein and J. Wolf: Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [ 18F]fluorothymidine (FLT-)PET. In: Lung Cancer 77, 3, 617-620 (2012).
doi: 10.1016/j.lungcan.2012.05.110
Kahraman, D., A. Holstein, M. Scheffler, T. Zander, L. Nogova, A. A. Lammertsma, R. Boellaard, B. Neumaier, M. Dietlein, J. Wolf and C. Kobe: Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. In: Clinical Nuclear Medicine 37, 11, 1058-1064 (2012).
doi: 10.1097/RLU.0b013e3182639747
Zander, T., M. Scheffler, L. Nogova, C. Kobe, W. Engel-Riedel, M. Hellmich, I. Papachristou, K. Toepelt, A. Draube, L. Heukamp, R. Buettner, Y. D. Ko, R. T. Ullrich, E. Smit, R. Boellaard, A. A. Lammertsma, M. Hallek, A. H. Jacobs, A. Schlesinger, K. Schulte, S. Querings, E. Stoelben, B. Neumaier, R. K. Thomas, M. Dietlein and J. Wolf: Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [18F] fluorodeoxyglucose and [ 18F] fluorothymidine positron emission tomography. In: Journal of Clinical Oncology 29, 13, 1701-1708 (2011).
doi: 10.1200/JCO.2010.32.4939
Zander, T., M. Scheffler, L. Nogova, C. Kobe, W. Engel-Riedel, M. Hellmich, I. Papachristou, K. Toepelt, A. Draube, L. Heukamp, R. Buettner, Y. D. Ko, R. T. Ullrich, E. Smit, R. Boellaard, A. A. Lammertsma, M. Hallek, A. H. Jacobs, A. Schlesinger, K. Schulte, S. Querings, E. Stoelben, B. Neumaier, R. K. Thomas, M. Dietlein and J. Wolf: Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [18F] fluorodeoxyglucose and [ 18F] fluorothymidine positron emission tomography. In: Journal of Clinical Oncology 29, 13, 1701-1708 (2011).
doi: 10.1200/JCO.2010.32.4939
http://edoc.mpg.de
The Max Planck Society does not take any responsibility for the content of this export.